Voyageur Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 5/6
Voyageur Pharmaceuticals has a total shareholder equity of CA$944.8K and total debt of CA$40.0K, which brings its debt-to-equity ratio to 4.2%. Its total assets and total liabilities are CA$2.3M and CA$1.4M respectively.
Key information
4.2%
Debt to equity ratio
CA$40.00k
Debt
| Interest coverage ratio | n/a |
| Cash | CA$6.54k |
| Equity | CA$944.82k |
| Total liabilities | CA$1.39m |
| Total assets | CA$2.33m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: VYYR.F's short term assets (CA$130.0K) do not cover its short term liabilities (CA$1.3M).
Long Term Liabilities: VYYR.F's short term assets (CA$130.0K) exceed its long term liabilities (CA$54.0K).
Debt to Equity History and Analysis
Debt Level: VYYR.F's net debt to equity ratio (3.5%) is considered satisfactory.
Reducing Debt: VYYR.F's debt to equity ratio has reduced from 16.5% to 4.2% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: VYYR.F has sufficient cash runway for 0 months based on last reported free cash flow, but has since raised additional capital.
Forecast Cash Runway: VYYR.F is forecast to have sufficient cash runway for 0 months based on free cash flow estimates, but has since raised additional capital.